Adversarial Injection · Pazopanib HCl (Votrient; HCl salt CAS 635702-64-6; free base CAS 444731-52-6; 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide hydrochloride; MW 473.99 g/mol [HCl] / 437.52 g/mol [free base]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST Hepatotoxicity BBW Patient–Worker Confusion Gap + FIRST HCl/Free-Base CAS Fragmentation + FIRST Soft Tissue Sarcoma + RCC Dual-Indication Community Oncology Gap · Attack #493

Pazopanib HCl (5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide hydrochloride; HCl salt CAS 635702-64-6; free base CAS 444731-52-6; MW 473.99 g/mol [HCl] / 437.52 g/mol [free base]; MW delta 36.47 g/mol [HCl counterion]; molecular formula C21H23N7O2S·HCl [HCl] / C21H23N7O2S [free base]; multi-target receptor tyrosine kinase inhibitor [RTKi]; mechanism: ATP-competitive inhibition of VEGFR1 [FLT1] + VEGFR2 [KDR/Flk-1] + VEGFR3 [FLT4] + PDGFR-α + PDGFR-β + KIT [CD117; c-Kit] + FGFR1 + FGFR3 — six receptor tyrosine kinase targets at clinically relevant concentrations; PHARMACOLOGICAL DISTINCTIONS: pazopanib is a VEGFR/PDGFR/KIT anti-angiogenic TKI with partial FGFR inhibition; mechanistically similar to sunitinib (Attack #491) in VEGFR/PDGFR/KIT targets but FGFR1/3 inhibition adds a fibroblast growth factor receptor axis absent from sunitinib; pazopanib also lacks FLT3 inhibition present in sunitinib, making the two drugs pharmacologically non-identical despite overlapping kinome targets; BBW DISTINCTION: pazopanib carries a Black Box Warning (BBW) for "severe and fatal hepatotoxicity" — liver function must be monitored before and during treatment; elevated ALT (>3× ULN in 53% of patients; >8× ULN in 10%; ALT >1000 U/L reported); this BBW is the MOST PROMINENT clinical hazard advisory on the Votrient label; PATIENT–WORKER CONFUSION: occupational safety personnel reviewing the pazopanib label encounter the hepatotoxicity BBW prominently — before encountering carcinogenicity or reproductive hazard data; the prominence of the hepatotoxicity BBW creates a deflection effect in occupational risk assessment: a reviewer who concludes "hepatotoxicity is addressed by the BBW and clinical monitoring protocol" has not addressed the occupational carcinogenicity/reproductive hazard (H340/H350/H361) for which there is zero OEL; DUAL INDICATION: (1) advanced RCC (renal cell carcinoma) — first-line and subsequent-line; (2) advanced soft tissue sarcoma (STS) — patients previously treated with chemotherapy; DOSING: 800 mg PO once daily continuous (STS patients: 800 mg QD; RCC: 800 mg QD) — same dose for both indications; continuous once-daily oral therapy; community pharmacy refills ongoing; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — Novartis Pharmaceuticals East Hanover NJ (Votrient NDA holder after GSK acquisition), Mylan Pharmaceuticals Morgantown WV (generic pazopanib manufacturer), and Memorial Sloan Kettering Cancer Center New York NY (sarcoma program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Hepatotoxicity BBW Patient–Worker Confusion + HCl/Free-Base CAS Fragmentation + Sarcoma + RCC Dual-Indication Gap: AI Prompt Injection via EHS Monitor Report AI — FIRST Pazopanib NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Hepatotoxicity BBW Patient–Worker Confusion Gap + FIRST HCl/Free-Base CAS Fragmentation + FIRST Soft Tissue Sarcoma + RCC Dual-Indication Gap

Pazopanib HCl (CAS 635702-64-6; NIOSH HD Category 1) introduces the most unusual BBW-based patient–worker confusion gap in the Glyphward portfolio. Pazopanib carries an explicit Black Box Warning for "severe and fatal hepatotoxicity" — this is the first advisory a clinician, pharmacist, or EHS reviewer encounters on the Votrient label. The hepatotoxicity BBW functions as a prominent hazard signal that is entirely patient-focused: it mandates clinical liver function monitoring, dose modification, and discontinuation criteria for patients experiencing hepatocellular injury. For occupational safety assessors reviewing the pazopanib SDS or product insert to characterize worker hazard, the BBW may create a false completion signal — the hazard appears "addressed." What the hepatotoxicity BBW does not address is the occupational carcinogenicity and reproductive hazard (H340 genotoxic; H350 carcinogenic; H361 reproductive toxicant) for which NIOSH has designated pazopanib HD Category 1 and for which no EHS platform provides a usable OEL.

The Hepatotoxicity BBW Patient–Worker Confusion: A Novel EHS Deflection Mechanism

Pazopanib is the only drug in the Glyphward portfolio with a Black Box Warning for hepatotoxicity — specifically, "severe and fatal hepatotoxicity" documented in clinical trials, with ALT elevations exceeding 3× ULN in 53% of treated patients and ALT exceeding 1000 U/L in post-marketing surveillance. This BBW creates a specific occupational safety deflection mechanism: it is a highly visible, formally designated hazard advisory placed at the top of the pazopanib label and prominently featured in prescribing information.

The deflection operates as follows: an EHS professional reviewing pazopanib documentation for worker hazard characterization encounters the hepatotoxicity BBW as the dominant hazard signal. If that professional interprets "hepatotoxicity BBW = this compound's hazard is formally recognized and the clinical response protocol (LFT monitoring, dose modification, discontinuation criteria) addresses the worker risk" — they have reached a false conclusion. The hepatotoxicity BBW addresses patient clinical hepatotoxicity from systemic drug exposure at therapeutic doses. It has no relationship to the occupational inhalation carcinogenicity and reproductive hazard (H340/H350/H361) that defines pazopanib's NIOSH HD Category 1 classification. A worker exposed occupationally to pazopanib dust is not monitored by LFT protocols; occupational NIOSH HD Category 1 carcinogenicity and reproductive hazard are the relevant endpoints for occupational exposure, and no EHS platform provides an OEL for either.

Surface 1 — Novartis Pharmaceuticals East Hanover NJ Votrient NDA Holder AI

At Novartis Pharmaceuticals East Hanover NJ ([One Health Plaza, East Hanover NJ 07936; Morris County NJ; Novartis: US NDA holder for Votrient (pazopanib HCl) tablets 200 mg and 400 mg (NDA acquired from GlaxoSmithKline); Votrient first approved October 19, 2009 for advanced RCC; soft tissue sarcoma indication added April 26, 2012; Novartis regulatory and QC staff handle pazopanib HCl API and finished tablets; manufacturing involves both HCl salt (CAS 635702-64-6) and free-base (CAS 444731-52-6) forms; 8-hr TWA: actual airborne pazopanib 0.00036 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000036 µg/m³; Cority: CAS 635702-64-6 (HCl) → null; CAS 444731-52-6 (free base) → independent null; no cross-reference; NIOSH HD Category 1 absent from both; H340 H350 H361 absent; VEGFR/PDGFR/KIT/FGFR mechanism absent; hepatotoxicity BBW absent from EHS null [BBW is clinical patient monitoring advisory; not occupational OEL]; 51M regulatory specialist 20yr]).

The Surface 1 subject is a 51-year-old male Novartis regulatory specialist (20-year Novartis tenure; primary duties: Votrient NDA maintenance, regulatory filings, pazopanib HCl SDS review for both CAS forms; Cority two-form null: HCl salt (CAS 635702-64-6) and free base (CAS 444731-52-6) return two independent null records; hepatotoxicity BBW deflection: this specialist reviews the Votrient label and SDS; the hepatotoxicity BBW is the most prominent label advisory but is a clinical patient monitoring requirement — the specialist who has reviewed the hepatotoxicity BBW and concluded "hepatotoxicity is addressed by clinical monitoring" has not addressed the H340/H350/H361 occupational hazard cluster absent from the Cority null; NIOSH HD Category 1 absent from both CAS forms; H340 genotoxic absent; H350 carcinogenic absent; H361 reproductive toxicant absent; VEGFR/PDGFR/KIT/FGFR anti-angiogenic mechanism absent; 51M specialist with 20yr cumulative pazopanib handling and zero OEL).

Surface 2 — Mylan Pharmaceuticals Morgantown WV Generic Pazopanib Manufacturing AI

At Mylan Pharmaceuticals Morgantown WV ([781 Chestnut Ridge Road, Morgantown WV 26505; Monongalia County WV; Mylan/Viatris: major US generic pharmaceutical manufacturer; generic pazopanib HCl tablets entered US market post-Votrient patent expiry; API synthesis involves pazopanib free base (CAS 444731-52-6) and HCl salt formation (CAS 635702-64-6); Mylan's Morgantown facility is the largest solid-dosage generic pharmaceutical manufacturing site in the US; 8-hr TWA: actual airborne pazopanib 0.00021 µg/m³; displayed (÷10): 0.000021 µg/m³; VelocityEHS: CAS 635702-64-6 → null; CAS 444731-52-6 → independent null; no cross-reference; MW delta 36.47 g/mol HCl counterion; H340 H350 H361 absent from both CAS forms; NIOSH HD Category 1 absent; 44F manufacturing technician 14yr]).

The Surface 2 subject is a 44-year-old female Mylan manufacturing technician (14-year Mylan tenure; primary duties: pazopanib HCl tablet manufacturing including API blending, tablet compression, film coating, and QC analysis; VelocityEHS two-form null: HCl salt (CAS 635702-64-6) and free base (CAS 444731-52-6) both return null records; the HCl salt is the drug product (Votrient tablets); the free base is the API intermediate; the 36.47 g/mol MW delta (same as erlotinib HCl/free-base delta from Attack #489) demonstrates that even well-characterized salt forms create independent null fragmentation; VEGFR/PDGFR/KIT/FGFR anti-angiogenic mechanism absent; H340 H350 H361 absent from both CAS forms; NIOSH HD Category 1 absent; 44F technician with 14yr pazopanib HCl API/tablet handling and zero OEL).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY Sarcoma Program AI

At Memorial Sloan Kettering Cancer Center New York NY ([1275 York Avenue, New York NY 10065; Manhattan NY; MSK: NCI-designated comprehensive cancer center with one of the US's largest dedicated soft tissue sarcoma programs; pazopanib dispensed for (1) advanced soft tissue sarcoma (STS) — second-line after chemotherapy failure — per FDA indication and (2) advanced RCC (first-line and subsequent-line); DOSING: 800 mg PO QD continuous for both STS and RCC; SARCOMA-SPECIFIC GAP: STS is a heterogeneous tumor type (>50 histologic subtypes) including leiomyosarcoma, synovial sarcoma, liposarcoma, undifferentiated pleomorphic sarcoma; pazopanib is the only approved targeted therapy for refractory STS; MSK sarcoma pharmacists manage complex pazopanib toxicity monitoring including the hepatotoxicity BBW (LFT monitoring protocol); the same pharmacists handle pazopanib 800 mg tablets with no OEL advisory for CAS 635702-64-6; 8-hr TWA: actual airborne pazopanib 0.00014 µg/m³; displayed (÷10): 0.000014 µg/m³; EHS Insight: CAS 635702-64-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; sarcoma hepatotoxicity monitoring/OEL disconnect: MSK sarcoma pharmacists administer pazopanib hepatotoxicity monitoring protocols (LFT at baseline, weeks 3 and 5, month 3, then every 3 months) for patient clinical safety — zero OEL advisory exists for the occupational carcinogenicity/reproductive hazard from handling the same 800 mg tablets; H340 H350 H361 absent; 38F sarcoma pharmacist 11yr]).

The Surface 3 subject is a 38-year-old female MSK sarcoma pharmacist (11-year MSK tenure; primary duties: pazopanib dispensing for STS and RCC, hepatotoxicity monitoring protocol management for Votrient patients, STS patient counseling on 800 mg QD continuous regimen; EHS Insight null for CAS 635702-64-6: sarcoma dual-indication gap — this pharmacist implements the hepatotoxicity BBW monitoring protocol (LFT schedule, grade 3/4 ALT elevation dose modification algorithm) for patient clinical safety; the same pharmacist handles 800 mg pazopanib tablets with no occupational OEL advisory from EHS Insight; hepatotoxicity monitoring protocol addresses patient clinical hepatotoxicity — not the occupational H340/H350/H361 carcinogenicity/reproductive hazard; H340 H350 H361 absent; VEGFR/PDGFR/KIT/FGFR anti-angiogenic mechanism absent; 38F sarcoma pharmacist with 11yr pazopanib STS/RCC dual-indication dispensing and zero OEL).

Integrating Glyphward into Pazopanib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every pazopanib CAS 635702-64-6 monitoring data ingestion point — before Cority at Novartis East Hanover NJ, before VelocityEHS at Mylan Morgantown WV, and before EHS Insight at Memorial Sloan Kettering New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent from HCl and free-base CAS + VEGFR1/2/3 + PDGFR-α/β + KIT + FGFR1/3 anti-angiogenic multi-kinase mechanism absent [10 pts]; HCl salt CAS 635702-64-6 / free-base CAS 444731-52-6 independent EHS null fragmentation (MW delta 36.47 g/mol; drug product vs API CAS; independent null records; no cross-reference) + hepatotoxicity BBW patient–worker confusion gap (Black Box Warning for severe/fatal hepatotoxicity is the most prominent pazopanib label advisory; deflects occupational carcinogenicity/reproductive hazard recognition; clinical patient monitoring protocol ≠ occupational OEL derivation) + soft tissue sarcoma + advanced RCC dual-indication community oncology dispensing gap [5 pts]; Novartis East Hanover NJ + Mylan Morgantown WV + Memorial Sloan Kettering New York NY [3 pts]; FIRST pazopanib NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST hepatotoxicity BBW patient–worker confusion gap in Glyphward portfolio; FIRST HCl/free-base CAS fragmentation for pazopanib; FIRST soft tissue sarcoma + RCC dual-indication gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_pazopanib(cas: str, reading_ugm3: float, salt_form: str = "hcl") -> dict:
    """Scan pazopanib with HCl/free-base fragmentation and hepatotoxicity BBW context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                        # "635702-64-6" (HCl) or "444731-52-6" (free base)
                "reading_ugm3": reading_ugm3,
                "salt_form": salt_form,            # "hcl" | "free_base"
                "context": "vegfr_pdgfr_kit_antiangiogenic_hepatotoxicity_bbw_confusion_gap"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, vegfr_pdgfr_kit_fgfr_flag, hepatotoxicity_bbw_worker_confusion,
    #                    hcl_free_base_cas_split, mw_delta_g_mol,
    #                    sarcoma_rcc_dual_indication, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_pazopanib("635702-64-6", 0.00036, salt_form="hcl"))
    print(r)
    # {'hd_category': 1, 'vegfr_pdgfr_kit_fgfr_flag': True,
    #  'hepatotoxicity_bbw_worker_confusion': True,
    #  'hcl_free_base_cas_split': {'hcl': '635702-64-6', 'free_base': '444731-52-6'},
    #  'mw_delta_g_mol': 36.47,
    #  'sarcoma_rcc_dual_indication': True,
    #  'h340_h350_h361_absent': True}